Why the study?
What is the role of monocytes in heart failure, and should monocyte activation be considered a therapeutic target?
What is the role of monocytes in heart failure, and should monocyte activation be considered a therapeutic target?
This review highlights the dual role of monocytes in heart failure, suggesting that promoting their tissue repair functions could be a novel therapeutic strategy.
Answers are grounded in this paper and cite their sources.
Does not support altering monocyte therapies in HF practice; leaves open activation strategies for prospective trials.
Monocytes play an important role in immune defence, inflammation, and tissue remodelling. Nevertheless, the role of monocytes in cardiovascular disease is obscure. Indeed, monocytes infiltrate dysfunctional tissue and augment tissue damage and are actively involved in tissue regeneration and healing. In support of the latter, recent studies have provided data on the functional and structural plasticity of monocytes. Monocytes are also actively involved in processes associated with tissue regeneration such as angiogenesis and vasculogenesis, either by producing pro-angiogenic factors or even by evolving to structural components of the vascular wall. This review article provides an overview on whether monocytes represent deteriorating immune overreaction in heart failure (HF), or a desperate attempt for tissue repair or physiological compensation in the failing heart. Perhaps, it is time to reconsider our attitude towards monocytes and consider more 'monocyte activation' rather than 'monocyte suppression' as a potential therapeutic target in HF.
No takes yet. Share an insight, caveat, or question.
Apostolakis et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: